Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK962040 dose-ranging study on levodopa pharmacokinetics in Parkinson's disease with delayed gastric emptying
2011-004438-32Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing GSK962040 plus levodopa with Placebo plus levodopa (2 arms). Primary endpoints: Dose-normalized levodopa AUC(0-4), Dose-normalized levodopa Cmax and 3 more. Started Apr 2012; status: completed.
02
Drugs
camicinal
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2011-004438-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004438-32.